Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.49), $0.10 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• H.C. Wainwright Reiterates Buy Rating on Lifeward (LFWD)
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04